A subcutaneous formulation of rituximab has been shown to have a similar efficacy and safety profile as intravenous rituximab in the treatment of follicular lymphoma. The international, phase 3 SABRINA study of more than 400 patients found 1400mg subcutaneous or 375mg/m2 intravenous rituximab in addition to chemotherapy achieved similar overall response rates at the end of induction therapy (84.4 ...
Subcut rituximab matches IV for follicular lymphoma
By Mardi Chapman
25 May 2017